Five sessions presented at the European Respiratory Society Congress 2023 were selected by Assembly 8, consisting of thoracic surgeons and lung transplant professionals. Highlights covering management of adult spontaneous pneumothorax, malignant pleural effusion, infectious and immune-mediated complications after lung transplantation, as well as the pro and con debate on age limit in lung transplantation and results of the ScanCLAD study were summarised by early career members, supervised by the assembly faculty.

Alma Mater Studiorum University of Bologna Bologna Italy

Baskent University Faculty of Medicine Chest Diseases Department Ankara Turkey

Division of Thoracic Surgery Department of Medical and Surgical Sciences of the Alma Mater Studiorum University of Bologna Bologna Italy

Giovanni Battista Morgagni Luigi Pierantoni Hospital Forlì Italy

Prague Lung Transplant Program Department of Pneumology 2nd Faculty of Medicine Charles University University Hospital Motol Prague Czech Republic

Program of Minimally Invasive Thoracic Surgery and New Technologies Policlinic Hospital Department of Surgery and Medical Specialties University of Catania Catania Italy

Pulmonology La Madonnina Reggio Calabria Reggio Calabria Italy

Sir Ganga Ram Hospital New Delhi India

Thoracic Surgery and Lung Transplantation King Faisal Specialist Hospital and Research Center Riyadh Saudi Arabia

Transplant Center IRCCS Policlinico San Matteo Foundation Pavia Italy

Unit of Thoracic Surgery San Camillo Forlanini Hospital Rome Italy

Villa aurora Hospital Reggio Calabria Reggio Calabria Italy

Zobrazit více v PubMed

MacDuff A, Arnold A, Harvey J. Management of spontaneous pneumothorax: British Thoracic Society pleural disease guideline 2010. Thorax 2010; 65: Suppl. 2, ii18–ii31. doi:10.1136/thx.2010.136986 PubMed DOI

Tschopp JM, Bintcliffe O, Astoul P, et al. . ERS task force statement: diagnosis and treatment of primary spontaneous pneumothorax. Eur Respir J 2015; 46: 321–335. doi:10.1183/09031936.00219214 PubMed DOI

Vuong NL, Elshafay A, Thao LP, et al. . Efficacy of treatments in primary spontaneous pneumothorax: a systematic review and network meta-analysis of randomized clinical trials. Respir Med 2018; 137: 152–166. doi:10.1016/j.rmed.2018.03.009 PubMed DOI

Brown SGA, Ball EL, Perrin K, et al. . Conservative versus interventional treatment for spontaneous pneumothorax. N Engl J Med 2020; 382: 405–415. doi:10.1056/nejmoa1910775 PubMed DOI

Marx T, Joly LM, Parmentier AL, et al. . Simple aspiration versus drainage for complete pneumothorax: a randomized noninferiority trial. Am J Respir Crit Care Med 2023; 207: 1475–1485. doi:10.1164/rccm.202110-2409OC PubMed DOI

Migliore M, Di Maria G, Criscione A, et al. . Clinico-pathological findings in stage-I primary spontaneous pneumothorax: analysis of 19 cases and literature review. Eur Surg 2013; 45: 83–86. doi:10.1007/s10353-012-0169-5 DOI

Gordillo Altamirano FL, Barr JJ. Phage therapy in the postantibiotic era. Clin Microbiol Rev 2019; 32: e00066-18. doi:10.1128/CMR.00066-18 PubMed DOI PMC

Cesta N, Pini M, Mulas T, et al. . Application of phage therapy in a case of a chronic hip-prosthetic joint infection due to Pseudomonas aeruginosa: an Italian real-life experience and in vitro analysis. Open Forum Infect Dis 2023; 10: ofad051. doi:10.1093/ofid/ofad051 PubMed DOI PMC

Verleden SE, Von der Thüsen J, Roux A, et al. . When tissue is the issue: a histological review of chronic lung allograft dysfunction. Am J Transplant 2020; 20: 2644–2651. doi:10.1111/ajt.15864 PubMed DOI

Vanstapel A, Goldschmeding R, Broekhuizen R, et al. . Connective tissue growth factor is overexpressed in explant lung tissue and broncho-alveolar lavage in transplant-related pulmonary fibrosis. Front Immunol 2021; 12: 661761. doi:10.3389/fimmu.2021.661761 PubMed DOI PMC

Jonigk D, Rath B, Borchert P, et al. . Comparative analysis of morphological and molecular motifs in bronchiolitis obliterans and alveolar fibroelastosis after lung and stem cell transplantation. J Pathol Clin Res 2017; 3: 17–28. doi:10.1002/cjp2.60 PubMed DOI PMC

Verleden GM, Glanville AR, Lease ED, et al. . Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment – a consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant 2019; 38: 493–503. doi:10.1016/j.healun.2019.03.009 PubMed DOI

Jagasia MH, Greinix HT, Arora M, et al. . National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2015; 21: 389–401. doi:10.1016/j.bbmt.2014.12.001 PubMed DOI PMC

Pang Y, Charya AV, Keller MB, et al. . The ISHLT chronic lung allograft dysfunction consensus criteria are applicable to pulmonary chronic graft-versus-host disease. Blood Adv 2022; 6: 4196–4207. doi:10.1182/bloodadvances.2021006885 PubMed DOI PMC

Bos S, Beeckmans H, Vanstapel A, et al. . Pulmonary graft-versus-host disease and chronic lung allograft dysfunction: two sides of the same coin? Lancet Respir Med 2022; 10: 796–810. doi:10.1016/S2213-2600(22)00001-7 PubMed DOI

Kitko CL, Pidala J, Schoemans HM, et al. . National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group report. Transplant Cell Ther 2021; 27: 545–557. doi:10.1016/j.jtct.2021.03.033.Kitko PubMed DOI PMC

Williams KM, Cheng GS, Pusic I, et al. . Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2016; 22: 710–716. doi:10.1016/j.bbmt.2015.10.009 PubMed DOI PMC

Vos R, Vanden ER, Ruttens D, et al. . Montelukast in chronic lung allograft dysfunction after lung transplantation. J Heart Lung Transplant 2019; 38: 516–527. doi:10.1016/j.healun.2018.11.014 PubMed DOI

Li D, Duan Q, Weinkauf J, et al. . Azithromycin prophylaxis after lung transplantation is associated with improved overall survival. J Heart Lung Transplant 2020; 39: 1426–1434. doi:10.1016/j.healun.2020.09.006 PubMed DOI

Bergeron A, Chevret S, Granata A, et al. . Effect of azithromycin on airflow decline-free survival after allogeneic hematopoietic stem cell transplant: the ALLOZITHRO randomized clinical trial. JAMA 2017; 318: 557–566. doi:10.1001/jama.2017.9938 PubMed DOI PMC

Zeiser R, Polverelli N, Ram R, et al. . Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med 2021; 385: 228–238. doi:10.1056/nejmoa2033122 PubMed DOI

Hefazi M, Langer KJ, Khera N, et al. . Extracorporeal photopheresis improves survival in hematopoietic cell transplant patients with bronchiolitis obliterans syndrome without significantly impacting measured pulmonary functions. Biol Blood Marrow Transplant 2018; 24: 1906–1913. doi:10.1016/j.bbmt.2018.04.012 PubMed DOI

Wolff D, Hilgendorf I, Wagner-Drouet E, et al. . Changes in immunosuppressive treatment of chronic graft-versus-host disease: comparison of 2 surveys within allogeneic hematopoietic stem cell transplant centres in Germany, Austria, and Switzerland. Biol Blood Marrow Transplant 2019; 25: 1450–1455. doi:10.1016/j.bbmt.2019.03.003 PubMed DOI

DeFilipp Z, Kim HT, Yang Z, et al. . Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials. Blood Adv 2022; 6: 6263–6270. doi:10.1182/bloodadvances.2022008095 PubMed DOI PMC

Wertheimer T, Dohse M, Afram G, et al. . Abatacept as salvage therapy in chronic graft-versus-host disease – a retrospective analysis. Ann Hematol 2021; 100: 779–787. doi:10.1007/s00277-021-04434-x PubMed DOI PMC

Koshy AG, Kim HT, Liegel J, et al. . Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood 2023; 141: 2932–2943. doi:10.1182/blood.2022019107 PubMed DOI

Kontoyiannis DP, Marr KA, Park BJ, et al. . Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis 2010; 50: 1091–1100. doi:10.1086/651263 PubMed DOI

Pappas PG, Alexander BD, Andes DR, et al. . Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50: 1101–1111. doi:10.1086/651262 PubMed DOI

Neofytos D, Fishman JA, Horn D, et al. . Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010; 12: 220–229. doi:10.1111/j.1399-3062.2010.00492.x PubMed DOI

Hosseini-Moghaddam SM, Ouédraogo A, Naylor KL, et al. . Incidence and outcomes of invasive fungal infection among solid organ transplant recipients: a population-based cohort study. Transpl Infect Dis 2020; 22: e13250. doi:10.1111/tid.13250 PubMed DOI

Pennington KM, Baqir M, Erwin PJ, et al. . Antifungal prophylaxis in lung transplant recipients: a systematic review and meta-analysis. Transpl Infect Dis 2020; 22: e13333. doi:10.1111/tid.13333 PubMed DOI PMC

Bhaskaran A, Mumtaz K, Husain S. Anti-Aspergillus prophylaxis in lung transplantation: a systematic review and meta-analysis. Curr Infect Dis Rep 2013; 15: 514–525. doi:10.1007/s11908-013-0380-y PubMed DOI

Pilarczyk K, Haake N, Heckmann J, et al. . Is universal antifungal prophylaxis mandatory in adults after lung transplantation? A review and meta-analysis of observational studies. Clin Transplant 2016; 30: 1522–1531. doi:10.1111/ctr.12854 PubMed DOI

Phoompoung P, Villalobos APC, Jain S, et al. . Risk factors of invasive fungal infections in lung transplant recipients: a systematic review and meta-analysis. J Heart Lung Transplant 2022; 41: 255–262. doi:10.1016/j.healun.2021.09.014 PubMed DOI

Husain S, Bhaskaran A, Rotstein C, et al. . A strategy for prevention of fungal infections in lung transplantation: role of bronchoalveolar lavage fluid galactomannan and fungal culture. J Heart Lung Transplant 2018; 37: 886–894. doi:10.1016/j.healun.2018.02.006 PubMed DOI

Wingard JR, Carter SL, Walsh TJ, et al. . Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116: 5111–5118. doi:10.1182/blood-2010-02-268151 PubMed DOI PMC

Wang J, Zhou M, Xu JY, et al. . Comparison of antifungal prophylaxis drugs in patients with hematological disease or undergoing hematopoietic stem cell transplantation: a systematic review and network meta-analysis. JAMA Netw Open 2020; 3: e2017652. doi:10.1001/jamanetworkopen.2020.17652 PubMed DOI PMC

Bose P, McCue D, Wurster S, et al. . Isavuconazole as primary antifungal prophylaxis in patients with acute myeloid leukemia or myelodysplastic syndrome: an open-label, prospective, phase 2 study. Clin Infect Dis 2021; 72: 1755–1763. doi:10.1093/cid/ciaa358 PubMed DOI PMC

Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. . Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis 2016; 16: 828–837. doi:10.1016/S1473-3099(16)00071-2 PubMed DOI

Leard LE, Holm AM, Valapour M, et al. . Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2021; 40: 1349–1379. doi:10.1016/j.healun.2021.07.005 PubMed DOI PMC

Zhou AL, Karius AK, Ruck JM, et al. . Outcomes of lung transplant candidates aged ≥70 years during the lung allocation score era. Ann Thorac Surg 2023; in press [10.1016/j.athoracsur.2023.04.046]. doi:10.1016/j.athoracsur.2023.04.046 PubMed DOI PMC

Singer LG, Chowdhury NA, Faughnan ME, et al. . Effects of recipient age and diagnosis on health-related quality-of-life benefit of lung transplantation. Am J Respir Crit Care Med 2015; 192: 965–973. doi:10.1164/rccm.201501-0126OC PubMed DOI

Venado A, McCulloch C, Greenland JR, et al. . Frailty trajectories in adult lung transplantation: a cohort study. J Heart Lung Transplant 2019; 38: 699–707. doi:10.1016/j.healun.2019.03.006 PubMed DOI PMC

Singer JP, Christie JD, Diamond JM, et al. . Development of the Lung Transplant Frailty Scale (LT-FS). J Heart Lung Transplant 2023; 42: 892–904. doi:10.1016/j.healun.2023.02.006 PubMed DOI PMC

Lehr CJ, Schold JD, Arrigain S, et al. . New OPTN/UNOS data demonstrates higher than previously reported waitlist mortality for lung transplant candidates supported with ECMO. J Heart Lung Transplant 2023; 42: 1399–1407. doi:10.1016/j.healun.2023.04.017 PubMed DOI PMC

Iyanna N, Chan EG, Ryan JP, et al. . Lung transplantation outcomes in recipients aged 70 years or older and the impact of center volume. J Clin Med 2023; 12: 5372. doi:10.3390/jcm12165372 PubMed DOI PMC

Dellgren G, Lund TK, Raivio P, et al. . Effect of once-per-day tacrolimus versus twice-per-day ciclosporin on 3-year incidence of chronic lung allograft dysfunction after lung transplantation in Scandinavia (ScanCLAD): a multicentre randomised controlled trial. Lancet Respir Med 2024; 12: 34–44. doi:10.1016/S2213-2600(23)00293-X PubMed DOI

Hachem RR, Yusen RD, Chakinala MM, et al. . A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J Heart Lung Transplant 2007; 26: 1012–1018. doi:10.1016/j.healun.2007.07.027 PubMed DOI

Treede H, Glanville AR, Klepetko W, et al. . Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation. J Heart Lung Transplant 2012; 31: 797–804. doi:10.1016/j.healun.2012.03.008 PubMed DOI